Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced p...

FDA Device Recall #Z-1249-2025 — Class II — February 3, 2025

Recall Summary

Recall Number Z-1249-2025
Classification Class II — Moderate risk
Date Initiated February 3, 2025
Status Ongoing
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Beckman Coulter, Inc.
Location Chaska, MN
Product Type Devices
Quantity 498 US; 1576 OUS

Product Description

Access Erythropoietin (EPO), Catalog Number - A16364 a glycoprotein (~30,400 Daltons) produced primarily by the kidney, is the principal factor regulating red blood cell production (erythropoiesis) in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of EPO in the circulation increases and this leads to increased production of red blood cells.

Reason for Recall

Affected lot (439363) exhibited a negative dose drop of -22% with native patient samples compared to alternate reagent lots. Patient samples tested with the affected lot may demonstrate repeatable falsely decreased results, which may lead to improper diagnosis or repeat testing.

Distribution Pattern

Domestic distribution to AL AR AZ CA CT FL ID IL IN KS MA MI NC NE NJ NY OH OR PA TN TX UT WA WV. International distribution to Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Philippines, Russian Federation, Saudi Arabia, Slovakia, Spain, United Kingdom of Great Britain and Northern Ireland

Lot / Code Information

Catalog A16364 UDI-DI 15099590201838 Lot 439363

Other Recalls from Beckman Coulter, Inc.

Recall # Classification Product Date
Z-1235-2026 Class II CellMek SPS Sample Preparation System, REF: C44... Dec 23, 2025
Z-1025-2026 Class II Beckman Coulter UniCel Dxl 600, Part numbers: ... Nov 26, 2025
Z-1026-2026 Class II Beckman Coulter UniCel Dxl 800, Part numbers: ... Nov 26, 2025
Z-1221-2026 Class II COULTER DxH Diluent, REF 628017 COULTER DxH EC... Nov 10, 2025
Z-0889-2026 Class II Access 2 Reaction Vessels, individual, disposab... Nov 7, 2025

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.